PWMG
CPRX

Prestige Wealth Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Prestige Wealth Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$9.3K – 1077
2022
Q4 		$9.3K Buy
+500
New +$7.7K ﹤0.01% 476

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prestige Wealth Management Group's CPRX Position: Q1 2023 in Review

Prestige Wealth Management Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 500 shares — an estimated $9.3K sold.

Prestige Wealth Management Group first reported a position in CPRX in Q4 2022 and held it in 1 quarter. The position peaked at $9.3K in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Prestige Wealth Management Group reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Prestige Wealth Management Group sold 500 Catalyst Pharmaceutical shares in Q1 2023, an estimated $9.3K.
  • Prestige Wealth Management Group first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 1 quarter.
  • Prestige Wealth Management Group's Catalyst Pharmaceutical position peaked at $9.3K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Prestige Wealth Management Group's 13F filing for Q1 2023, filed 16 May 2023.